Eversight, a leading global nonprofit eye bank, today announced the availability of Descemet’s membrane endothelial keratoplasty (DMEK) tissue preloaded in EndoGlide™, offering corneal surgeons a fourth preloaded DMEK option to further streamline surgery and reduce cost.
As illustrated, preloaded DMEK EndoGlide™ utilizes an endothelium-in or trifold loading method, whereas traditional injectable DMEK grafts are loaded endothelium-out. Using an anterior chamber maintainer for infusion, the graft is pulled into the eye with specialized forceps through a 2.65mm incision. The DMEK graft has a natural tendency to unscroll in the correct orientation because it was loaded endothelium-in.
The pull-through technique and endothelium-in attribute of preloaded DMEK EndoGlide™ provide added control of the graft and its orientation, which is critical to the success of the procedure and may make DMEK more achievable in complex eyes.
“DMEK provides favorable clinical outcomes for patients and is an efficient use of surgeon time and healthcare resources,” said Michael Titus, Vice President of Clinical Operations, Eversight. “As adoption of DMEK continues to grow, we listened to surgeons who aim to make the procedure available to more of their patients. Eversight is dedicated to providing improved tissue preparation services like preloaded DMEK EndoGlide™ that can ultimately improve access to quality eye care.”
Contact your Eversight representative to learn more about DMEK in EndoGlide™—one of four preloaded DMEK options available from Eversight—and access free on-demand training to confidently adopt this surgical technique.
Read the full press release from Eversight.